Streetbeat News

Regulatory

TCRX

TScan Therapeutics is advancing its TSC-101 treatment for hematological malignancies, with key data from the phase 1 ALLOHA study expected by the end of 2025. The company plans a pivotal study for AML, MDS, and ALL patients undergoing HSCT in the second half of 2025, pending regulatory feedback. Additionally, TScan is developing multiplex TCR-Ts for solid tumors, with phase 1 PLEXI-T trial data anticipated in late 2025.

Portfolio Pulse from

March 07, 2025 | 4:45 pm

SHEL

The article discusses the notification and public disclosure of transactions by persons discharging managerial responsibilities, in line with EU and UK market abuse regulations.

Portfolio Pulse from

March 07, 2025 | 4:30 pm

CURLF

The marijuana industry faces uncertainty with Donald Trump's presidency, affecting both large MSOs like Trulieve and small-batch operators. Increased taxes and regulatory concerns challenge small operators.

Portfolio Pulse from

March 07, 2025 | 4:30 pm

LTRY

Lottery.com Inc. has regained compliance with Nasdaq's listing rules as its stock price has remained above $1.00 for the past 20 days, avoiding a reverse stock split.

Portfolio Pulse from

March 07, 2025 | 4:15 pm

COIN

HOOD

MSTR

President Trump is set to host a crypto summit at the White House, with executives from major crypto companies like Coinbase, Crypto.com, and Robinhood. Trump has proposed a strategic crypto reserve to boost the U.S. crypto industry. Bitcoin prices surged post-election but have recently declined.

Portfolio Pulse from

March 07, 2025 | 4:00 pm

V

Senator Richard Blumenthal has requested Visa to provide detailed plans and documents regarding its payments services deal with Elon Musk's social media platform, X. The request is partly due to Musk's influence on the CFPB.

Portfolio Pulse from

March 07, 2025 | 3:15 pm

BAYRY

Bayer AG has warned US lawmakers it may stop selling its Roundup weedkiller in the US unless stronger legal protections are provided to shield the company from product liability lawsuits. Bayer has already paid $10 billion to settle claims related to Roundup's alleged cancer risks.

Portfolio Pulse from

March 07, 2025 | 3:00 pm

STXS

Stereotaxis is expected to receive FDA approval for its MAGiC system this fall, which could end its cash burn. The company has set conservative sales targets for 2025, focusing on existing system backlog and MAGiC usage in Europe. MAGiC Sweep is anticipated to generate significant recurring revenue.

Portfolio Pulse from

March 07, 2025 | 2:30 pm